# Product Specification Sheet

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Leukadherin-1 (LA1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catalog Number:</td>
<td>C5385-2 (powder)</td>
</tr>
<tr>
<td></td>
<td>C5385-2s (10mM in DMSO)</td>
</tr>
<tr>
<td>Package Size:</td>
<td>2 mg</td>
</tr>
</tbody>
</table>

**Technical information:**

- Chemical Formula: C₂₂H₁₃NO₄S₂
- CAS #: 344897-95-6
- Molecular Weight: 421.49
- Purity: >98%
- Formulation: White solid
- Solubility: Soluble in DMSO up to 50 mM
- Chemical Name: (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
- Storage: Store solid powder at 4°C desiccated; Store DMSO solution at -20°C.

**Handling:**

- For C5385-2 (powder), add 474 μL of DMSO to make 10 mM solution.
- For C5385-2s, before open the vial, centrifuge the vial at 500rpm x 1 min in a 50 mL conical tube to ensure full sample recovery.

**Biological Activity:** Leukadherin-1 (LA1), a novel small molecule agonists of integrin CD11b/CD18, can increase the extent of CD11b/CD18-dependent cell adhesion of transfected cells and of primary human and mouse neutrophils (EC₅₀ =4μM in vitro), which resulted in decreased chemotaxis and transendothelial migration. LA1 can also decrease leukocyte recruitment and reduced arterial narrowing after injury in rats. Moreover, compared to a known integrin antagonist, LA1 preserved kidney function better in a mouse model of experimental nephritis. It inhibited leukocyte recruitment by increasing leukocyte adhesion to the inflamed endothelium, which was reversed with a blocking antibody.

**Reference:**


For Technical Support: technical@cellagentech.com

*For research use only, not for clinical or diagnostic use.*